Rapidly Growing Mycobacteria Infection in Patients with Cancer

Infectious Disease Service, Dept of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Clinical Infectious Diseases (Impact Factor: 8.89). 08/2010; 51(4):422-34. DOI: 10.1086/655140
Source: PubMed


Rapidly growing mycobacteria (RGM) have been associated with various clinical syndromes in immunocompetent and immunocompromised hosts. The risk factors and outcomes of RGM infection in patients with cancer have not been clearly defined.
Data were derived from 2 distinct sources. Demographic and clinical data were collected for all patients with cancer at Memorial Sloan-Kettering Cancer Center with a culture positive for RGM from January 1999 through December 2008. We also reviewed the literature for studies describing RGM infection in patients with cancer.
During the 10-year period, 28 patients with cancer at Memorial Sloan-Kettering Cancer Center had cultures positive for RGM. Most cases occurred in patients with solid tumors and were confined to the lung. A review of the literature identified 313 additional patients with cancer and RGM infection. Combining our series data with cases from the literature, we defined 3 distinct syndromes: pulmonary disease, which occurred in 158 patients (47%); bloodstream infection, occurring in 151 patients (45%); and disseminated infection involving at least 1 end organ, affecting 26 persons (8%). The syndromes differed by age of onset, underlying cancer, main RGM species, and outcome. Persons with bloodstream infection typically were young and had an excellent outcome; those with disseminated infection were older, had pronounced immunosuppression, and had a very poor prognosis.
RGM infections in patients with cancer comprise 3 distinct disorders with different risk factors, predominant mycobacterial species, and prognoses. In turn, the approach to management, including number and duration of antimycobacterial drugs, may be fundamentally different for various patients with cancer who receive a diagnosis of RGM infection.

Full-text preview

Available from:
  • Source
    • "In the Redelman-Sidi's study, the median duration of antibiotics was 8 weeks (range, 5 days to 29 weeks) (Redelman-Sidi and Sepkowitz, 2010). Interestingly, the patients treated for less than a month had the same outcomes as the patients treated for longer than a month (Sidi and Sepkowitz, 2010). Hawkins's group recommended parenteral therapy for 2 to 4 weeks followed by oral therapyof ciprofloxacin, ofloxacin, doxycycline, minocycline, erythromycin, clarithromycin , azithromycin, amikacin, and imipenem were determined by E-test, and MICs of cefoxitin, trimethoprim/sulfamethoxazole, tobramycin, and amoxicillin/ clavulanate were determined by disk diffusion. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We present a patient with double hit Burkitt's like lymphoma who developed a catheter-related bloodstream infection due to Mycobacterium phocaicum that was identified by rpoB gene sequencing. His infection resolved with 7 weeks of antibiotics and port-a-cath removal.
    Full-text · Article · Mar 2013 · Diagnostic microbiology and infectious disease
  • Source
    • "Several strains have intrinsic resistance to many antibiotics, which complicates treatment. M. abscessus is the most pathogenic of this group and occasionally causes pulmonary infection, usually but not invariably in immunocompromised patients or people with underlying lung disease such as cystic fibrosis [2,3]. We could find no reports of this infection complicating GPA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Backgound Granulomatosis with polyangitis (Wegener’s) is a vasculitic disease predominantly affecting the lungs, skin, kidneys, ears, nose and throat. Mycobacterium abscessus is an uncommon rapidly growing mycobacterium causing sporadic lung disease. This is the first report of both GPA and Mycobacterium abscessus pulmonary disease reported in literature. Case Presentation We present a case report of a 33 year old Caucasian man with relapsing disease complicated by pulmonary infection with Mycobacterium abscessus. He subsequently required bilateral cochlear implantation for progressive sensori-neural hearing loss. His M. abscessus was treated successfully with a prolonged course of antimicrobial therapy. His Granulomatosis with polyangitis (Wegener’s) relapsed towards the end of antimicrobial therapy and required treatment. Shortly after completing his antimicrobial therapy and relapse, he developed progressive dyspnea due to pulmonary fibrosis. Conclusion The potential causes of his progressive dyspnoea are discussed including the potential role of his underlying disease and treatment.
    Full-text · Article · Sep 2012 · BMC Pulmonary Medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Members of the Mycobacterium chelonae-abscessus complex represent Mycobacterium species that cause invasive infections in immunocompetent and immunocompromised hosts. We report the detection of a new pathogen that had been misidentified as M. chelonae with an atypical antimicrobial drug susceptibility profile. The discovery prompted a multicenter investigation of 26 patients. Almost all patients were from the northeastern United States, and most had underlying sinus or pulmonary disease. Infected patients had clinical features similar to those with M. abscessus infections. Taxonomically, the new pathogen shared molecular identity with members of the M. chelonae-abscessus complex. Multilocus DNA target sequencing, DNA-DNA hybridization, and deep multilocus sequencing (43 full-length genes) support a new taxon for these microorganisms. Because most isolates originated in Pennsylvania, we propose the name M. franklinii sp. nov. This investigation underscores the need for accurate identification of Mycobacterium spp. to detect new pathogens implicated in human disease.
    Preview · Article · Sep 2011 · Emerging Infectious Diseases
Show more